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compared to best supportive care alone in patients with refractory or 
recurrent disease within 6 months of initial platinum therapy.
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ERCC1 and TOPOIIa mRNA levels predict response to platinum/
etoposide chemotherapy and survival of small-cell lung cancer 
patients. 
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Background: This study was designed to evaluate the predictive role 
of mRNA quantiﬁcation of three genes potentially related to platinum/
etoposide therapy in small-cell lung cancer (SCLC): ERCC1, RRM1 
and TOPOIIα.
Methods: A retrospective analysis was therefore performed on 103 
consecutive patients with either limited stage (LS) or extensive stage 
(ES) SCLC. Total RNA was extracted from microdissected sections of 
103 formalin-ﬁxed, parafﬁn embedded pre-treatment biopsies of SCLC 
patients. Relative quantiﬁcation for ERCC1, RRM1 and TOPOIIα plus 
an internal reference gene (b-actin) was done by Real Time PCR using 
intron-spanning primers. ERCC1 was evaluated also by immunohisto-
chemistry (IHC) with a semi-quantitative score. 
Results: Eighty-ﬁve samples (83%) were successfully ampliﬁed by 
Real Time PCR and a gene expression level was detectable in all 
samples. Out of these 85 cases, 45 (53%) had LS SCLC and 40 (47%) 
ES SCLC; overall response rate (RR) to chemotherapy was 65% (56 
cases), median survival was 9.9 months. 
IHC staining of ERCC1 was positive in 2 out of 85 patients with no 
correlation with clinico-pathological factors. A signiﬁcant correla-
tion emerged between ERCC1 and RRM1 mRNA levels (Rs=0.34, 
p=0.001). 
Low TOPOIIα expression was associated to increased RR in LS 
patients (p=0.025) and TOPOIIα levels were lower in patients who had 
a complete response than in patients with either partial responses or no 
response (p=0.01). At univariate analysis LS patients with low ERCC1 
mRNA levels had longer median survival (14.9 months vs. 9.9 months, 
p=0.01), while RRM1 and TOPOIIα levels showed no signiﬁcant inﬂu-
ence on survival. At multivariate analysis, ERCC1 was conﬁrmed as 
an independent prognostic factors for survival in LS patients, together 
with performance status (PS) and response to chemotherapy. No signiﬁ-
cant prognostic role was found for ERCC1, RRM1 and TOPOIIα in 
patients with ES SCLC. 
Conclusions: Pharmacogenomics have been widely studied in ad-
vanced NSCLC, while poor efforts have so far been devoted on such 
topic in SCLC. ERCC1 and TOPOIIα mRNA levels could represent 
new reliable markers to predict response to treatment and clinical out-
come in subgroups of SCLC patients. The path to the individualization 
of therapy through selection of patients based on pharmacogenomic 
data should be pursued to improve prognosis of SCLC. 
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HGF/c-Met axis modulate Topoisomerase-I activity and cell 
viability in small cell lung cancer
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Small cell lung cancer (SCLC) is a very aggressive malignancy, which 
metastasizes very early in its course. Current therapies have apparently 
reached their maximum efﬁcacy, prompting the search for new thera-
pies and the combination of new therapies with current treatment. Pre-
viously we identiﬁed the c-Met receptor tyrosine kinase to be expressed 
and functional in SCLC. We have shown that hepatocyte growth factor 
(HGF), the ligand for c-Met causes tyrosine phosphorylation of c-Met 
on the pY1230/1234/1235 autophosphorylation site, in addition to ac-
tivation of important downstream signaling intermediates, such as Akt 
and ERK 1/2. There was also strong correlation between phosphor-Met 
and with Topoisomerase I. Utilizing the novel c-Met tyrosine kinase 
inhibitor, SU11274, we have shown that this HGF mediated signaling 
can be abrogated in a dose-dependent fashion. Since Topoisomerase 
I inhibition is a relatively effective approach for treating SCLC, we 
determined whether Topoisomerase I inhibition (using the Irinotecan 
metabolite SN38) would be synergistic when combined with the novel 
c-Met inhibitor, SU11274, to reduce cell viability in SCLC cell lines. 
Synergism was evident in both of the SCLC cell lines (H69 and H345) 
used for the study, but was enhanced in the H69 cell line. This was 
apparently due to the R988C mutation in the c-Met juxtamembrane do-
main. We also show that the HGF/c-Met axis can modulate Topoisom-
erase I activity and this modulation can be abrogated by SU11274. This 
combination of SU11274 and Topoisomerase I inhibitor could provide 
an efﬁcacious combination for the treatment of SCLC. 
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Gene therapy represents a novel treatment strategy for small cell lung 
cancer (SCLC), which is a highly aggressive malignancy characterized 
by poor prognosis. Due to the metastatic nature of SCLC, treatment 
must be performed systemically requiring a high level of targeting. At 
this laboratory transcriptionally targeted gene therapy has been devel-
oped utilizing promoters identiﬁed as highly and speciﬁcally active in 
SCLC. In addition a promising nonviral gene delivery system is being 
tested and optimized in vivo. 
In general only few therapeutic genes have been tested for SCLC gene 
therapy. The aim of the present project is to test various therapeutic 
genes with very different mechanism of action, and compare their ef-
ﬁcacy in vitro. The genes were cloned to be regulated from the SCLC 
speciﬁc promoter, INSM1, tested by transient transfections into SCLC 
cell lines and cell survival evaluated with MTT assay. 
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Restoration of the tumor suppressor genes P53, Retinoblastoma, FHIT 
and FUS1 had only minimal effect on cell death, although the tumor 
suppressors are functional defective in >80 % of SCLC. 
Modulating the oncogene activity of Bcl-2 was attempted by introduc-
ing a truncated version of Bax, with increased apoptotic activity. Inhibi-
tion of Hsp70-mediated cancer survival was attempted by the introduc-
tion of Hsp40 J domain, a dominant negative gene inhibiting Hsp70 
activity. Although the gene products activated cellular death pathways 
in transfected cells, no signiﬁcant cell death was observed.
In contrast suicide gene strategies showed great potential for SCLC 
gene therapy. The suicide gene system herpes simplex virus thymidine 
kinase (HSVtk) with the prodrug ganciclovir (GCV) had already been 
tested and implemented at the laboratory showing >50 % cell death in 
vitro and tumor regression in vivo. HSVtk efﬁcacy was improved by 
the replacement of GCV with penciclovir (PCV), which demonstrated 
signiﬁcant less toxicity to untransfected cells. Another suicide gene 
system was implemented for testing: the yeast cytosine deaminase 
(YCD)gene either alone or fused with the yeast uracil phosphoribosyl-
transferase (YUPRT) gene and combined with the prodrug 5-FC. The 
YCD/YUPRT fusion gene showed superior efﬁcacy, mediating 90 % 
SCLC cell death. This dual suicide gene strategy targets in contrast to 
HSVtk/GCV or PCV, both DNA and RNA synthesis, also causing cell 
death to non-proliferating, dormant cancer cells. The strategy demon-
strated signiﬁcant bystander cytotoxicity due to the diffusion of toxic 
metabolites to nearby cancer cells, showing potential to overcome 
the low transfection efﬁciency currently characterizing in vivo gene 
therapy.
An update will be presented.
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Dose-response relationships in extensive small cell lung cancer and 
implications for resistance mechanisms.
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Background: We assessed clinical dose-response curve (DRC) 
shape in extensive small cell lung cancer (SCLC) to gain insight into 
predominant resistance mechanism. We hypothesized DRC shape (log 
% cell survival vs linear dose) reﬂects resistance mechanisms, with a 
shoulder on the DRC indicating “active resistance” (excess resistance 
factor), decreased slope indicating “non-saturable passive resistance” 
(factor alteration/mutation) and a terminal plateau indicating “saturable 
passive resistance” (factor deﬁciency/saturation). We previously re-
ported that NSCLC DRCs ﬂatten at higher doses, suggesting saturable 
passive resistance.
Methods: Published SCLC clinical trials were reviewed. Response 
rates were converted into estimated mean tumor cell kill for each trial, 
assuming % tumor cell kill is proportional to % reduction in tumor 
volume. Complete remissions were assumed to represent 99% cell kill, 
partial remissions a 65-99% (mean 83%) cell kill, stable disease 13% 
cell kill and progression 0% cell kill. Mean % cell kill for a study was 
calculated based on % patients in each response category. Log mean % 
cell survival was plotted vs planned dose-intensity for each agent. Us-
ing data both weighted and unweighted for number of patients per trial, 
meta-regression analyses and nonlinear regression analyses were used 
to assess DRC shape.
Results: In metaregression analysis, efﬁcacy failed to vary signiﬁcantly 
with dose for all drugs assessed (cisplatin, carboplatin, etoposide, cy-
clophosphamide, ifosfamide, epirubicin and paclitaxel). For all agents, 
DRCs had reduced slopes or ﬂattened at higher doses.
Conclusions: While maximal mean % cell kill was greater with SCLC 
than in earlier NSCLC studies, outcomes were similar with respect to 
DRC ﬂattening at higher doses, suggesting that drug efﬁcacy is ulti-
mately limited by a deﬁciency or saturation of something required for 
drug effect. Lack of beneﬁt of high dose in most solid tumors suggests 
that this may also apply to most other epithelial malignancies. Based 
on DRC ﬂattening and other clinical and preclinical observations, we 
hypothesize: 1) With the ﬁrst chemotherapy cycle, quiescent cells are 
resistant and survive even high chemotherapy doses. 2) Cells surviving 
the ﬁrst cycle may upregulate expression of active resistance factors, 
permitting tumor regrowth between chemotherapy cycles or imme-
diately after chemotherapy. 3) Tumors unable to upregulate active resis-
tance sufﬁciently will down-regulate transporters, metabolism, etc, and 
will survive further chemotherapy through quiescence, with resumption 
of tumor growth delayed until some time beyond last chemotherapy 
administration. 4) Increasing drug doses may partially overcome active 
resistance, but tumors will then revert to saturable passive resistance. 
5) Active resistance factors play a role in differences in treatment ef-
ﬁcacy between patients and between studies, but the characteristic that 
is common to all is the ﬂattening of the DRC at high drug doses. 6) 
Major progress vs epithelial tumors will require enhanced targeting of 
quiescent cells. 7) The ability to cure some patients with limited SCLC 
with chemotherapy alone (and the enhanced cure rates when adjuvant 
therapy is used in localized NSCLC) suggests that the biology may 
possibly be different in localized vs advanced disease. Support: NCI 
Cancer Center Support Grant 5-P30 CA16672 to UTMDACC
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Introduction: Standard treatment for limited-stage small cell lung can-
cer is concurrent chemoradiation. The initial planning tumor volume 
(PTV) typically decreases in size during radiotherapy. For large tumors 
or in case of difﬁculty in meeting normal tissue constraints, our practice 
is to conduct a second simulation before the last third of the treatment 
course, usually before delivering 25 Gy, and irradiate a smaller boost 
volume for the remainder. We examined the effect of this practice on 
tissue sparing and local control.
Methods: Twenty-two patients with limited-stage small cell lung cancer 
were treated with deﬁnitive chemoradiation in 2006. Patients had three-
dimensional or intensity modulated radiation therapy developed on a 
Pinnacle treatment planning system using heterogeneity corrections and 
pre-determined dose-volume constraints. The volume of lung at 20 Gy 
(V20) was kept ≤35 Gy, the volume of heart at 40 Gy ≤40%, and the 
volume of esophagus at 50 Gy ≤50%; spinal cord maximum dose was 
45 Gy. For replanned patients, dose-volume histograms were plotted for 
the original plan versus the second plan and the composite plan.
Results: Of 22 patients, six underwent resimulation and replanning. 
The median decrease in PTV volume at the time of the replan was 56% 
